Movement disorders : official journal of the Movement Disorder Society · 2026
Hyperhomocysteinemia and Vitamin B Deficiency as Potential Aggravating Factors in Huntington's Disease: A Prospective Monocentric Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Puisieux Salomé, Pourié Elise, Bonnet Céline, Hopes Lucie, Frismand Solène, Bronner Myriam, Roth Virginie, Wandzel Marion, Sloboda Natacha, Lambert Laetitia, Oussalah Abderrahim, Julien Amélia, Rotaru Irina, Guéant-Rodriguez Rosa-Maria, Guéant Jean Louis, Bossenmeyer-Pourié Carine, Renaud Mathilde
Аннотация
BACKGROUND: Although not confirmed, some studies have suggested that elevated homocysteine levels are common in patients with Huntington's disease (HD). Its clinical relevance remains unclear.
OBJECTIVES: We aimed to assess vitamin B and homocysteine levels in HD patients and explore the relationships among hyperhomocysteinemia, vitamin B deficiency, and motor symptom progression.
METHODS: In this monocentric case-control study, 77 HD patients were prospectively included between January 2020 and June 2023 at Nancy University Hospital. As controls, biological data were obtained retrospectively from 87 individuals referred to the Metabolic Medicine Department between January 2017 and February 2025. HD patients underwent clinical (Unified Huntington Disease Rating Scale-Motor) and biochemical (vitamin B and homocysteine levels) evaluations. Fisher's exact test, Wilcoxon test, or Student's t-test were used, with P < 0.05 considered significant.
RESULTS: HD patients-both symptomatic and premanifest-had significantly higher homocysteine levels than did controls. Hyperhomocysteinemia was found in 36 patients (≈48%) and was associated with faster motor progression (P < 0.001).
CONCLUSIONS: Hyperhomocysteinemia appears to be frequent in HD patients and may represent a risk factor contributing to phenotypic variability. These findings support a potential link between altered one-carbon metabolism and HD. Further longitudinal and mechanistic studies are needed to clarify the clinical and pathophysiological relevance of homocysteine metabolism in HD and to determine whether targeting hyperhomocysteinemia could have therapeutic implications. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
OBJECTIVES: We aimed to assess vitamin B and homocysteine levels in HD patients and explore the relationships among hyperhomocysteinemia, vitamin B deficiency, and motor symptom progression.
METHODS: In this monocentric case-control study, 77 HD patients were prospectively included between January 2020 and June 2023 at Nancy University Hospital. As controls, biological data were obtained retrospectively from 87 individuals referred to the Metabolic Medicine Department between January 2017 and February 2025. HD patients underwent clinical (Unified Huntington Disease Rating Scale-Motor) and biochemical (vitamin B and homocysteine levels) evaluations. Fisher's exact test, Wilcoxon test, or Student's t-test were used, with P < 0.05 considered significant.
RESULTS: HD patients-both symptomatic and premanifest-had significantly higher homocysteine levels than did controls. Hyperhomocysteinemia was found in 36 patients (≈48%) and was associated with faster motor progression (P < 0.001).
CONCLUSIONS: Hyperhomocysteinemia appears to be frequent in HD patients and may represent a risk factor contributing to phenotypic variability. These findings support a potential link between altered one-carbon metabolism and HD. Further longitudinal and mechanistic studies are needed to clarify the clinical and pathophysiological relevance of homocysteine metabolism in HD and to determine whether targeting hyperhomocysteinemia could have therapeutic implications. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.